Table 7.
Baseline characteristics in subgroup analysis.
| According to Treatment Interval | According to Concomitant Treatment | |||
|---|---|---|---|---|
| Interval of 2 Weeks | Interval Others | Dupilumab-Only Group |
Concomitant Treatment Group |
|
| EASI score (min–max) | 26.5 (14.0–60.0) | 26.0 (14.0–60.0) | 26.9 (14.0–60.0) | 31.7 (15.9–60.0) |
| NRS score (min–max) | 8.0 (2.0–10.0) | 8.0 (2.0–10.0) | 8.0 (2.0–10.0) | 9.0 (2.0–10.0) |
| POEM (min–max) | 25.5 (5.0–28.0) | 23.5 (12.0–28.0) | 24.0 (5.0–28.0) | 25.0 (9.0–28.0) |
| DLQI (min–max) | 23.0 (14.0–30.0) | 23.0 (14.0–30.0) | 23.0 (14.0–30.0) | 26.0 (14.0–29.0) |